Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 15, 2026
Citigroup (C) Delivers Q2 2026 Earnings Beat

Citigroup (C) Delivers Q2 2026 Earnings Beat

Key Takeaways

  • Citigroup reported Q2 2026 earnings per share of $3.15, beating the consensus estimate of approximately $2.67-$2.72.
  • The company released its second quarter 2026 results via press release on July 14, 2026, followed by an earnings call.
  • EPS growth reflects continued strength in core businesses amid favorable market conditions.
  • Investors are monitoring revenue trends and any updates on capital return plans.
  • The results mark another quarter of outperformance relative to analyst forecasts.

Why These Earnings Matter

Citigroup’s quarterly earnings provide a key window into the performance of one of the largest U.S. banks, with significant exposure to global markets, consumer banking, and institutional clients. Following solid results in the prior quarter, investors watch these reports closely for signs of sustained revenue growth, credit quality trends, and progress on strategic initiatives. The Q2 2026 release comes at a time when banking sector dynamics, including interest rate environments and trading activity, remain central to performance expectations.

The Reported Numbers

Citigroup reported earnings per share of $3.15 for the second quarter of 2026. This figure exceeded the consensus analyst estimate of $2.67 to $2.72. The company issued its official results on July 14, 2026. Detailed revenue figures and segment breakdowns were provided in the accompanying press release and earnings materials. The beat was driven primarily by stronger-than-expected performance in key operating areas. No specific forward guidance updates were highlighted in initial summaries beyond standard quarterly disclosures. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Market Response

Following the release of Q2 2026 results on July 14, 2026, market participants focused on the EPS beat and its implications for the bank’s trajectory. Sentiment heading into the report had been cautiously optimistic given prior performance, with attention on trading revenues and overall profitability. Post-release price action reflected investor interpretation of the numbers relative to expectations.

Looking Ahead

Investors will next focus on Citigroup’s upcoming third quarter results, scheduled for October 13, 2026. Key areas include trends in net interest income, trading and investment banking activity, and any shifts in credit loss provisions.

Broader economic indicators such as interest rate paths and global growth will continue to influence performance. Management commentary on expense management and capital allocation strategies remains important for assessing long-term positioning.

Additional catalysts could include regulatory updates or developments in the bank’s international operations. Monitoring these elements will help provide clarity on the sustainability of recent earnings momentum. From what I see, this is important because it highlights the bank’s ability to navigate evolving conditions.

Using AI Tools in My Research Process

When analyzing earnings like these, I often turn to Tickeron’s AI Screener to quickly filter through thousands of stocks and ETFs based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. This helps me compare C against peers in the banking sector using customizable criteria such as industry, market cap, and performance metrics. It streamlines the process of spotting trade ideas and market opportunities more efficiently than manual methods. AI Screener

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: C

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


C's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for C turned positive on August 04, 2026. Looking at past instances where C's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on C as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where C advanced for three days, in of 337 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

C moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for C crossed bearishly below the 50-day moving average on July 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where C declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

C broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for C entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 20, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: C's P/B Ratio (1.166) is slightly lower than the industry average of (1.949). P/E Ratio (14.420) is within average values for comparable stocks, (16.293). C's Projected Growth (PEG Ratio) (0.721) is slightly lower than the industry average of (1.624). Dividend Yield (0.019) settles around the average of (0.025) among similar stocks. C's P/S Ratio (2.633) is slightly lower than the industry average of (4.347).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. C’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

Notable companies

The most notable companies in this group are JPMorgan Chase & Co (NYSE:JPM), Bank of America Corp (NYSE:BAC), HSBC Holdings PLC (NYSE:HSBC), Wells Fargo & Co (NYSE:WFC), Citigroup (NYSE:C), Barclays PLC (NYSE:BCS).

Industry description

Major banks are among the biggest companies in the world, often times with global reach and market capitalizations in the multi-billions. Large banks often have multiple arms spanning different disciplines, from deposits, to investment banking, to wealth management and insurance. The biggest banks often have key competitive advantages over smaller players in the industry in terms of brand recognition, cost of capital, and efficiency. Think J.P. Morgan, Bank of America, Wells Fargo, and Citigroup.

Market Cap

The average market capitalization across the Major Banks Industry is 216.73B. The market cap for tickers in the group ranges from 1.04M to 947.12B. JPM holds the highest valuation in this group at 947.12B. The lowest valued company is BACRP at 1.04M.

High and low price notable news

The average weekly price growth across all stocks in the Major Banks Industry was 1%. For the same Industry, the average monthly price growth was 3%, and the average quarterly price growth was 17%. SAN experienced the highest price growth at 4%, while HSBC experienced the biggest fall at -4%.

Volume

The average weekly volume growth across all stocks in the Major Banks Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -9% and the average quarterly volume growth was -45%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 68
P/E Growth Rating: 29
Price Growth Rating: 39
SMR Rating: 8
Profit Risk Rating: 19
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
C
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a financial conglomerate

Industry MajorBanks

Profile
Details
Industry
Financial Conglomerates
Address
388 Greenwich Street
Phone
+1 212 559-1000
Employees
239000
Web
https://www.citigroup.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.